SEATTLE--(BUSINESS WIRE)--Light Sciences Oncology today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase III clinical trial comparing use of its Light Infusion Therapy™(Litx™) with a standard treatment for metastatic colorectal cancer in the liver (MCRC). The SPA for MCRC follows an August 2005 SPA for a Phase III trial of Litx in hepatocellular carcinoma (HCC).
